Interferon Beta-1b

What it is and how it works

Interferon beta-1b is a non-glycosylated recombinant interferon beta produced in Escherichia coli. It modulates the immune response in multiple sclerosis by reducing pro-inflammatory cytokines, inhibiting T-cell activation and limiting leucocyte migration across the blood–brain barrier.

Indications

Relapsing–remitting multiple sclerosis, secondary progressive MS with active disease, and a single demyelinating event (clinically isolated syndrome) at high risk of developing MS.

Dosage and administration (summary)

250 micrograms by subcutaneous injection every other day, with gradual dose titration over the first weeks of treatment.

Contraindications

Hypersensitivity to natural or recombinant interferon beta, human albumin or excipients; current severe depression and/or suicidal ideation; decompensated liver disease.

Warnings and precautions

Depression and suicidal ideation, hepatic injury, thrombotic microangiopathy, nephrotic syndrome, blood dyscrasias and thyroid dysfunction may occur; monitor blood counts and liver and thyroid function. Injection-site reactions, including necrosis, and flu-like symptoms are common. Use with caution in patients with seizure disorders or cardiac disease.

Pregnancy

May be used during pregnancy if clinically needed, based on available registry data.

Storage and supply

Store below 25 °C; do not freeze.

Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.